We have collected information about Anti-Her2 Immunoliposomes Enhanced Efficacy Attributable To Targeted Delivery for you. Follow the links to find out details on Anti-Her2 Immunoliposomes Enhanced Efficacy Attributable To Targeted Delivery.
https://www.ncbi.nlm.nih.gov/pubmed/11948130/
PURPOSE: Anti-HER2 immunoliposomes combine the tumor-targeting of certain anti-HER2 monoclonal antibodies (MAbs) with the pharmacokinetic and drug delivery capabilities of sterically stabilized liposomes.Author: John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby, Jose Baselga, Yvonne S...
https://clincancerres.aacrjournals.org/content/clincanres/8/4/1172.full.pdf
enhanced antitumor efficacy via targeted delivery. INTRODUCTION Immunoliposomes represent a novel strategy for tumor-targeted drug delivery (1). Immunoliposomes have become fea-sible as a result of parallel advances in the areas of liposome research and MAb5 technology, which in principle can now be combined for tumor-targeted drug delivery.Author: John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby, Jose Baselga, Yvonne S...
https://clincancerres.aacrjournals.org/content/8/4/1172
Apr 01, 2002 · We conclude that tumor-targeted drug delivery using anti-HER2 immunoliposomes can enhance the therapeutic index of dox chemotherapy and therefore may provide a particularly potent and useful therapy for cancers that involve HER2 overexpression.Author: John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby, Jose Baselga, Yvonne S...
https://www.sciencedirect.com/science/article/pii/S093964111630786X
Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy ... Taken together, our results support the clinical development of immunoliposomes for targeted delivery of PTX and RAP to HER2-positive breast cancer. ... improved drug efficacy, lower toxicity, enhanced pharmacokinetics and stability ...Author: Josimar O. Eloy, Josimar O. Eloy, Raquel Petrilli, Raquel Petrilli, Deise L. Chesca, Fabiano P. Sagg...
https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-020-00609-2
An example of such an approach utilizes immunoliposomes for Her2-positive breast cancer treatment . The incorporation of an anti-Her2 antibody fragment into the liposome vehicle led to the targeted delivery of the incorporated drug in in vitro and in vivo studies .
https://www.sciencedirect.com/science/article/pii/S154996341730179X
Based on the above observations, we hypothesized that the combination of Doxil and Metuximab will result in enhanced antitumor efficacy. Thus, the aims of this study were to develop CD147-targeted immunoliposomes containing doxorubicin (Anti-CD147 ILs-DOX) and study their effects on HCC in vitro and in vivo. Methods MaterialsAuthor: Jian Wang, Zhitao Wu, Guoyu Pan, Junsheng Ni, Fangyuan Xie, Beige Jiang, Lixin Wei, Jie Gao, Jie Gao...
Searching for Anti-Her2 Immunoliposomes Enhanced Efficacy Attributable To Targeted Delivery?
You can just click the links above. The data is collected for you.
